CLINICAL TRIALS PROFILE FOR TOLCAPONE
✉ Email this page to a colleague
All Clinical Trials for TOLCAPONE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00033059 ↗ | Assessment of Potential Interactions Between Cocaine and Tolcapone - 1 | Unknown status | National Institute on Drug Abuse (NIDA) | Phase 1 | 2001-07-01 | The purpose of this study is to assess the potential interactions between intravenous (IV) cocaine and tolcapone. |
| NCT00044083 ↗ | Clinical Trial of Tolcapone for Cognition in Schizophrenia | Terminated | National Institute of Mental Health (NIMH) | Phase 2 | 2002-08-01 | This study will evaluate whether Tolcapone improves cognition in healthy volunteers as well as patients with schizophrenia. Talcapone is a drug that has been FDA approved for Attention Deficit Disorder and allegedly increase the amount of the neurotransmitter dopamine in the frontal cortex of the brain. ... |
| NCT00548327 ↗ | The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype | Terminated | National Institute of Mental Health (NIMH) | Phase 2 | 2007-10-01 | This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Atomoxetine is a drug that has been Food and Drug Administration (FDA) approved for Attention Deficit Disorder and allegedly increase the amount of the neurotransmitter dopamine in the frontal cortex of the brain. |
| NCT00604591 ↗ | Effects of Tolcapone on Frontotemporal Dementia | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | 2011-07-01 | This study will test the effects of a medication called tolcapone on cognitive, behavioral, and language problems seen in patients with frontotemporal dementia (FTD). Tolcapone increases the amount of dopamine, a brain chemical that may be lowered in FTD. The study will see if tolcapone can improve thinking, behavior, and language in people with FTD and will look at the effects of the drug on brain activity. Patients with FTD who are between 40 and 85 years of age may be eligible for this study. Participants will be seen as outpatients at the Columbia University Medical Center approximately one a week for 4 weeks. They take tolcapone or a placebo (a look-alike pill with no active ingredient) during study week 1. During study week 3, those who took placebo during week 1 now take tolcapone for 1 week and those who took tolcapone now take placebo. In addition, patients undergo the following tests and procedures: - Neurological tests to evaluate attention, problem-solving and memory. These tests are repeated several times during the course of the study. - Test to look for a gene that affects the amount of dopamine in the brain, using blood samples collected in a previous study. - Blood draws four times during the study. - Functional MRI (fMRI) to learn about changes in brain regions that are involved in performing tasks. For fMRI, the patient lies on a table that can slide in and out of the scanner, a narrow metal cylinder surrounded by a magnetic field. The procedure takes about 60 minutes and is performed four times over the course of the . FMRI involves taking pictures of the brain during MRI while the subject performs a task so that changes in the brain that occur during these tasks can be studied. |
| NCT00604591 ↗ | Effects of Tolcapone on Frontotemporal Dementia | Completed | Columbia University | Phase 2 | 2011-07-01 | This study will test the effects of a medication called tolcapone on cognitive, behavioral, and language problems seen in patients with frontotemporal dementia (FTD). Tolcapone increases the amount of dopamine, a brain chemical that may be lowered in FTD. The study will see if tolcapone can improve thinking, behavior, and language in people with FTD and will look at the effects of the drug on brain activity. Patients with FTD who are between 40 and 85 years of age may be eligible for this study. Participants will be seen as outpatients at the Columbia University Medical Center approximately one a week for 4 weeks. They take tolcapone or a placebo (a look-alike pill with no active ingredient) during study week 1. During study week 3, those who took placebo during week 1 now take tolcapone for 1 week and those who took tolcapone now take placebo. In addition, patients undergo the following tests and procedures: - Neurological tests to evaluate attention, problem-solving and memory. These tests are repeated several times during the course of the study. - Test to look for a gene that affects the amount of dopamine in the brain, using blood samples collected in a previous study. - Blood draws four times during the study. - Functional MRI (fMRI) to learn about changes in brain regions that are involved in performing tasks. For fMRI, the patient lies on a table that can slide in and out of the scanner, a narrow metal cylinder surrounded by a magnetic field. The procedure takes about 60 minutes and is performed four times over the course of the . FMRI involves taking pictures of the brain during MRI while the subject performs a task so that changes in the brain that occur during these tasks can be studied. |
| NCT00906828 ↗ | Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors | Completed | Swedish Parkinson's Disease Foundation | Phase 4 | 2008-10-01 | The purpose of this study is to determine whether oral intake of COMT inhibitors affects the smooth plasma levodopa levels achieved by intestinal levodopa/carbidopa infusion in advanced Parkinson's disease patients. The hypothesis is that COMT inhibitors make plasma concentrations of levodopa more fluctuating. |
| NCT00906828 ↗ | Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors | Completed | Swedish Society for Medical Research | Phase 4 | 2008-10-01 | The purpose of this study is to determine whether oral intake of COMT inhibitors affects the smooth plasma levodopa levels achieved by intestinal levodopa/carbidopa infusion in advanced Parkinson's disease patients. The hypothesis is that COMT inhibitors make plasma concentrations of levodopa more fluctuating. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TOLCAPONE
Condition Name
Clinical Trial Locations for TOLCAPONE
Trials by Country
Clinical Trial Progress for TOLCAPONE
Clinical Trial Phase
Clinical Trial Sponsors for TOLCAPONE
Sponsor Name
